Synthesis and Three-Dimensional Quantitative Structure-Activity Relationship Analysis of H3 Receptor Antagonists Containing a Neutral Heterocyclic Polar Group

References

• (a) Arrang, J. M., Garbarg, M., and Schwartz, J.-C. (1985). Autoregulation of histamine release in brain by presynaptic H3-receptors. Neuroscience, 15, 553–562. (b) Arrang, J. M., Garbarg, M., and Schwartz, J.-C. (1987). Autoinhibition of histamine synthesis mediated by presynaptic H3-receptors. Neuroscience, 23, 149–157.
   PubMed Web of Science ®Google Scholar
• (a) Schlicker, E., Malinowska, B., Kathmann, M., and Göthert, M. (1994). Modulation of neurotransmitter release via histamine H3 heteroreceptors. Fundam. Clin. Pharmacol., 8, 128- 137. (b) Schlicker, E., Fink, K., Detzner, M., and Göthert, M. (1993). Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptors. J. Neural. Trasm.-Gen. Sect., 93, 1–10.
   Google Scholar
• Bertaccini, G., Coruzzi, G., and Poli E. (1998). Functional role of the histamine H3 receptors in peripheral tissues. In The Histamine H3 Receptor: A Target for New Drugs, edited by R. Leurs and H. Timmerman, Amsterdam: Elsevier Science B. V., pp. 59–112.
   Google Scholar
• (a) Brown, R. E., Stevens, D. R., and Haas, H. L. (2001). The physiology of brain histamine. Prog. Neurobiol., 63, 637–672. (b) Ghi, P., Fettetti, C., and Orsetti, M. (2001). Cognitive enhancing properties of thioperamide infused into the nucleus basalis magnocellularis of the rat. Inflamm. Res., 50, S78–S79.
   PubMed Web of Science ®Google Scholar
• Arrang, J. M., Garbarg, M., and Schwartz, J.-C. (1983). Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptors. Nature, 302, 832–837.
   PubMed Web of Science ®Google Scholar
• (a) Lovenberg, T. W., Roland, B. L., Wilson, S. J., Jiang, X. X., Huvar, A., Jackson, M. R., and Erlander, M. G. (1999). Cloning and functional expression of the human histamine H3 receptor. Mol. Pharmacol., 55, 1101–1107. (b) Ortho-McNeil Pharmaceutical, Inc.: WO0020011 (2000). The cloning of the human histamine H3 receptor. Exp. Opin. Ther. Patents, 10, 1607–1611.
   PubMed Web of Science ®Google Scholar
• (a) Lovenberg, T. W., Pyati, J., Chang, H., Wilson, S. J., and Erlander, M. G. (2000). Cloning of rat histamine H3 receptor reveals distinct species pharmacological profiles. J. Pharm. Exp. Ther., 293, 771–778. (b) Tardivel-Lacombe, J., Rouleau, A., Héron, A., Morisset, S., Pillot, C., Cochois, V., Schwartz, J.-C., and Arrang, J.-M. (2000). Cloning and cerebral expression of the guinea pig histamine H3 receptor: Evidence for two isoforms. Neuroreport, 11, 755–759.
   PubMed Web of Science ®Google Scholar
• (a) Oda, T., Morikawa, N., Saito, Y., Masuho, Y., and Matsumoto, S. (2000). Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J. Biol. Chem., 275, 36781–36786. (b) Morse, K. L., A resolution, whose extension was at least 4 a 3D-QSAR ANALYSIS OF H3 RECEPTOR ANTAGONISTS 77 Behan, J., Laz, T. M., West, R. E. Jr, Greenfeder, S. A., Anthes, J. C., Umland, S., Wan, Y., Hipkin, R. W., Gonsiorek, W., Shin, N., Gustafson, E. L., Qiao, X., Wang, S., Hedrick, J. A., Greene, J., Bayne, M., and Monsma, F. J. Jr (2001). Cloning and characterization of a novel human histamine receptor. J. Pharm. Exp. Ther., 296, 1058–1066. (c) Zhu, Y., Michalovich, D., Wu, H.-L., Tan, K. B., Dykto, G. M., Mannan, I. J., Boyce, R., Alston, J., Tierney, L. A., Li, X., Herrity, N. C., Vawter, L., Sarau, H. M., Ames, R. S., Davenport, C. M., Hieble, J. P., Wilson, S., Bergsma, D. J., and Fitzgerald, L. R. (2001). Cloning, expression, and pharmacological characterization of a novel human histamine receptor. Mol. Pharmacol., 59, 434- 441. (d) Liu, C., Ma, X.-J., Jiang, X., Wilson, J. S., Hofstra, C. L., Blevitt, J., Pyati, J., Li, X., Chai, W., Carruthers, N., and Lovenberg, T. W., (2001). Cloning and pharmacological characterization of a fourth histamine receptor (H4) expressed in bone marrow. Mol. Pharmacol., 59, 420–426. (e) Nguyen, T., Shapiro, D. A., George, S. R., Setola, V., Lee, D. K., Cheng, R., Rauser, L., Lee, S. P., Lynch, K. R., Roth, B. R., and O'Dowd, B. F. (2001). Discovery of a novel member of the histamine receptor family. Mol. Pharmacol., 59, 427–433.
   PubMed Web of Science ®Google Scholar
• (a) Leurs, R., Blandina, P., Tedford, C., and Timmerman, H. (1998). Therapeutic potential of histamine H3 receptor agonists and antagonists. Trends Pharmacol. Sci., 19, 177–183. (b) Leurs, R., Vollinga, R. C., and Timmerman, H. (1995). The medicinal chemistry and therapeutic potentials of ligands of the histamine H3 receptor. In Progress in Drug Research, edited by E. Jucker, Basel: Birkhauser Verlag, pp. 107–165.
   Google Scholar
• Ali, S. M., Tedford, C. E., Gregory, R., Handley, M. K., Yates, S. L., Hirt, W. W., and Phillips, J. G. (1999). Design, synthesis, and structure-activity relationships of acetylene-based histamine H3 receptor antagonists. J. Med. Chem., 42, 903–909.
   PubMed Web of Science ®Google Scholar
• Halpern, M. T. (1999). GT-2331 (Gliatech Inc.). Curr. Opin. CPNS Invest. Drugs, 1, 524–527.
   Google Scholar
• Stark, H., Ligneau, X., Arrang, J.-M., Schwartz, J.-C., and Schunack, W. (1998). General construction pattern of histamine H3-receptor antagonists: Change of a paradigm. Bioorg. Med. Chem. Lett., 8, 2011–2016.
   PubMed Web of Science ®Google Scholar
• (a) Stark, H., Lipp, R., Arrang, J. M., Garbarg, M., Schwartz, J. C., and Schunack, W. (1994). Acylated and alkylated histamine derivatives as new histamine H3-receptor antagonists. Eur. J. Med. Chem., 29, 695–700. (b) Stark, H., Lipp, R., Arrang, J.-M., Garbarg, M., Ligneau, X., Schwartz, J.-C., and Schunack, W. (1995). New potent histamine H3-receptor antagonists of the amide type. Eur. J. Pharm. Sci., 3, 95–104.
   Google Scholar
• Van der Goot, H., Schepers, M. J. P., Sterk, J. G., and Timmerman, H. (1992). Isothiourea analogues of histamine as potent agonists or antagonists of the histamine H3 receptor. Eur. J. Med. Chem., 27, 511–517.
   Web of Science ®Google Scholar
• Stark, H., Ligneau, X., Lipp, R., Arrang, J.-M., Schwartz, J.-C., and Schunack, W. (1997). Search for novel leads for histamine H3-receptor antagonists: Amine derivatives. Pharmazie, 52, 419–423.
   PubMed Web of Science ®Google Scholar
• Tozer, M. J., Buck, I. M., Cooke, T., Kalindjiaan, S. B., McDonald, I. M., Pether, M. J., and Steel, K. I. M. (1999). 4-Chlorobenzyl sulfonamide and sulfamide derivatives of histamine homologues: The design of potent histamine H3 receptor antagonists. Bioorg. Med. Chem. Lett., 9, 3103–3108.
   PubMed Web of Science ®Google Scholar
• Stark, H., Krause, M., Arrang, J.-M., Ligneau, X., Schwartz, J.-C., and Schunack, W. (1994). Unsymmetrically substituted guanidines as potent histamine H3-receptor antagonists. Bioorg. Med. Chem. Lett., 4, 2907–2912.
   Web of Science ®Google Scholar
• (a) Hüls, A., Purand, K., Reidemeister, S., Ligneau, X., Arrang, J.-M., Schwartz, J.-C., and Schunack, W. (1996). Novel histamine H3-receptor antagonists with benzyl ether structure or related moieties: Synthesis and structure-activity relationships. Arch. Pharm. Pharm. Med. Chem., 329, 379–385. (b) Hüls, A., Purand, K., Stark, H., Ligneau, X., Arrang, J.-M., Schwartz, J.-C., and Schunack, W. (1996). Diphenylmethyl ethers: Synthesis and histamine H3-receptor antagonist in vitro and in vivo activity. Bioorg. Med. Chem. Lett., 6, 2013–2018. (c) Ganellin, C. R., Fkyerat, A., Bang-Andersen, B., Athmani, S., Tertiuk, W., Garbarg, M., Ligneau, X., and Schwartz, J.-C. (1996). A novel series of (phenoxyalkyl)imidazoles as potent H3-receptor histamine antagonists. J. Med. Chem., 39, 3806- 3813. (d) Krause, M., Ligneau, X., Stark, H., Garbarg, M., Schwartz, J.-C., and Schunack, W. (1998). 4-Alkynylphenyl imidazolylpropyl ethers as selective histamine H3-receptor antagonists with oral central nervous system activity. J. Med. Chem., 41, 4171–4176. (e) Sasse, A., Sadek, B., Ligneau, X., Elz, S., Pertz, H. H., Luger, P., Ganellin, C. R., Arrang, J.-M., Schwartz, J.-C., Schunack, W., and Stark, H. (2000). New histamine H3-receptor ligands of the proxifan series: Imoproxifan and other selective antagonists with high oral in vivo potency. J. Med. Chem., 43, 3335–3343. (f) Stark, H., Sadek, B., Krause, M., Hüls, A., Ligneau, X., Ganellin, C. R., Arrang, J.-M., Schwartz, J.-C., and Schunack, W. (2000). Novel histamine H3-receptor antagonists with carbonyl-substituted 4-(3-(phenoxy)propyl)-1H-imidazole structures like ciproxifan and related compounds. J. Med. Chem., 43, 3987–3994.
   Google Scholar
• (a) Bordi, F., Mor, M., Plazzi, P. V., Silva, C., Morini, G., Caretta, A., Barocelli, E., and Impicciatore, M. (1992). Synthesis and binding assays of H3-receptor ligands. Farmaco, 47, 1343–1365. (b) Bordi, F., Mor, M., Morini, G., Plazzi, P. V., Silva, C., Vitali, T., and Caretta, A. (1994). QSAR study on H3-receptor affinity of benzothiazole derivatives of thioperamide. Il Farmaco, 49, 153–166. (c) Plazzi, P. V., Bordi, F., Mor, M., Morini, G., Caretta, A., Barocelli, E., and Vitali, T. (1995). Heteroarylaminoethyl and heteroarylthioethyl imidazoles. Synthesis and H3 receptor affinity. Eur. J. Med. Chem., 30, 881–889. (d) Plazzi, P. V., Mor, M., Bordi, F., Silva, C., Rivara, S., Caretta, A., Ballabeni, V., Impicciatore, M., and Vitali, T. (1997). Ligands of the histamine H3-receptor: New potent antagonists of the 2-thioimidazole type. Il Farmaco, 52, 295–302. (e) Mor, M., Bordi, F., Silva, C., Rivara, S., Crivori, P., Plazzi, P. V., Ballabeni, V., Caretta, A., Barocelli, E., Impicciatore, M., Carrupt, P.-A., and Testa, B. (1997). H3-receptor antagonists: Synthesis and structure-activity relationships of para- and meta-substituted 4(5)-phenyl-2-[[2-[4(5)-imidazolyl]ethyl]thio]imidazoles. J. Med. Chem., 40, 2571–2578.
   PubMedGoogle Scholar
• (a) Ganellin, C. R., Hosseini, S. K., Khalaf, Y. S., Tertiuk, W., Arrang, J.-M., Garbarg, M., Ligneau, X., and Schwartz, J.-C. (1995). Design of potent non-thiourea H3-receptor histamine antagonists. J. Med. Chem., 38, 3342–3350. (b) Clitherow, J. W., Beswick, P., Irving, W. J., Scopes, D. I. C., Barnes, J. C., Clapham, J., Brown, J. D., Evans, D. J., and Hayes, A. G. (1996). Novel 1,2,4-oxadiazoles as potent and selective histamine H3 receptor antagonists. Bioorg. Med. Chem. Lett., 6, 833- 838.
   PubMed Web of Science ®Google Scholar
• (a) Kononowicz, K. K., Ligneau, X., Stark, H., Schwartz, J.-C., and Schunack, W. (1995). Azines and diazines as potential histamine H3-receptor antagonists. Arch. Pharm. (Weinheim), 328, 445–450. (b) Kononowicz, K. K., Ligneau, X., Schwartz, J.-C., and Schunack, W. (1995). Pyrazoles as potential histamine H3-receptor antagonists. Arch. Pharm. (Weinheim), 328, 469–472. (c) Ganellin, C. R., Leurquin, F., Piripitsi, A., Arrang, J.-M., Garbarg, M., Ligneau, X., Schunack, W., and Schwartz, J.-C. (1998). Synthesis of potent non-imidazole histamine H3-receptor antagonists. Arch. Pharm. Pharm. Med. Chem., 331, 395–404. (d) Walczynski, K., Guryn, R., Zuiderveld, O. P., and Timmerman, H. (1999). Non-imidazole histamine H3 ligands. Part I. Synthesis of 2-(1-piperazinyl)- and 2-(hexahydro-1H-1,4-diazepin-1-yl)benzothiazole derivatives 78 S. RIVARA et al. as H3 antagonists with H1 blocking activities. Farmaco, 54, 684–694. (e) Walczynski, K., Guryn, R., Zuiderveld, O. P., and Timmerman, H. (1999). Non-imidazole histamine H3 ligands. Part 2: New 2-substituted benzothiazoles as histamine H3 antagonists. Arch. Farm. Pharm. Med. Chem., 332, 389- 398. (f) Linney, I. D., Buck, I. M., Harper, E. A., Kalindjian, S. B., Pether, M. J., Shankley, N. P., Watt, G. F., and Wright, P. T. (2000). Design, synthesis and structure-activity relationships of novel non-imidazole histamine H3 receptor antagonists. J. Med. Chem., 43, 2362–2370. (g) Meier, G., Apelt, J., Reichert, U., Graßmann, S., Ligneau, X., Elz, S., Leurquin, F., Ganellin, R. C., Schwartz, J.-C., Schunack, W., and Stark, H. (2001). Influence of imidazole replacement in different structural classes of histamine H3-receptor antagonists. Eur. J. Pharm. Sci., 13, 249–259. (h) Apelt, J., Ligneau, X., Pertz, H. H., Arrang, J.-M., Ganellin C. R., Swartz, J.-C., Schunack W., and Stark, H. (2002). Development of a new class of nonimidazole histamine H3 receptor ligands with combined inhibitory histamine Nmethyltransferase activity. J. Med. Chem., 45, 1128–1141. (i) Faghih, R., Dwight, W., Gentles, R., Phelan, K., Esbenshade, T. A., Ireland, L., Miller, T. R., Kang, C.-H., Fox, G. B., Gopalakrishnan, S. M., Hancock, A. A., and Bennani, Y. L. (2002). Structure-activity relationships of non-imidazole H3 receptor ligands. Part 1. Bioorg. Med. Chem. Lett., 12, 2031- 2034. (j) Faghih, R., Dwight, W., Black, L., Liu, H., Gentles, R., Phelan, K., Esbenshade, T. A., Ireland, L., Miller, T. R., Kang, C.-H., Krueger, K. M., Fox, J. B., Hancock, A. A., and Bennani, Y. L. (2002). Structure-activity relationships of non-imidazole H3 receptor ligands. Part 2: Binding preference for D-amino acids motifs. Bioorg. Med. Chem. Lett., 12, 2035–2037. (k) Meier, G., Ligneau X., Partz, H. H., Ganellin, C. R., Schwartz, J.-C., Schunack, W., and Stark, H. (2002). Piperidino-hydrocarbon compounds as novel non-imidazole histamine H3-receptor antagonists. Bioorg. Med. Chem., 10, 2535–2542.
   Google Scholar
• (a) Yates, S. L., Phillips, J. G., Gregory, R., Pawlowski, P., Fadnis, L., Khan, M. A., Ali, S. M., and Tedford, C. E. (1999). Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazolyl histamine H3 receptor ligands. J. Pharm. Exp. Ther., 289, 1151–1159. (b) Tedford, C. E., Phillips, J. G., Gregory, R., Pawlowski, P., Fadnis, L., Khan, M. A., Ali, S. M., Handley, M. K., and Yates, S. L. (1999). Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands. J. Pharm. Exp. Ther., 289, 1160–1168.
   PubMed Web of Science ®Google Scholar
• De Esch, I. J. P., Gaffar, A., Menge, W. M. P. B., and Timmerman, H. (1999). Synthesis and histamine H3 receptor activity of 4-(n-alkyl)-1H-imidazoles and 4-(!-phenylalkyl)-1H-imidazoles. Bioorg. Med. Chem., 7, 3003–3009.
   PubMed Web of Science ®Google Scholar
• Arrang, J.-M., Garbarg, M., Lancelot, J.-C., Lecomte, J.-M., Pollard, H., Robba, M., Schunack, W., and Schwartz, J. C. (1987). Highly potent and selective ligands for histamine H3 receptors. Nature, 327, 117–123.
   PubMed Web of Science ®Google Scholar
• (a) Plazzi, P. V., Mor, M., Silva, C., Bordi, F., Morini, G., Crivori, P., and Caretta, A. (1996). Rat protein binding and cerebral phospholipid affinity of the H3-receptor antagonist thioperamide. J. Pharm. Pharmacol., 48, 712–717. (b) Silva, C., Mor, M., Bordi, F., Rivara, S., Caretta, A., Ballabeni, V., Barocelli, E., and Plazzi, P. V. (1997). Plasma concentration and brain penetration of the H3-receptor antagonist thioperamide in rats. Il Farmaco, 52, 457–462. (c) Silva, C., Plazzi, P. V., Bordi, F., Rivara, S., Vacondio, F., Zuliani, V., Caretta, A., and Mor, M. (2000). Structure-property relationships on histamine H3-antagonists: Binding of phenyl-substituted alkylthioimidazole derivatives to rat plasma proteins. Il Farmaco, 55, 239–245.
   Google Scholar
• De Esch, I. J. P., Mills, J. E. J., Perkins, T. D. J., Romeo, G. Hoffmann, M., Wieland, K., Leurs, R., Menge, W. M. P. B., Nederkoorn, P. H. J., Dean, P. M., and Timmerman, H. (2001). Development of a pharmacophore model for histamine H3 receptor antagonists, using the newly developed molecular modeling program SLATE. J. Med. Chem., 44, 1666- 1674.
   Google Scholar
• Stark, H., Sippl, W., Ligneau, X., Arrang, J.-M., Ganellin, R. C., Schwartz, J.-C., and Schunack W. (2001). Different antagonist binding properties of human and rat histamine H3 receptors. Bioorg. Med. Chem. Lett., 11, 951–954.
   PubMed Web of Science ®Google Scholar
• Overberger, C. G., and Vorchheimer, N. (1963). Imidazole-containing polymers. Synthesis and polymerization of the monomer 4(5)-vinylimidazole. J. Am. Chem. Soc., 85, 951- 955.
   Web of Science ®Google Scholar
• Woods, G. F., and Sanders, H. (1946). Studies in pyrane chemistry. J. Am. Chem. Soc., 68, 2483–2485.
   Web of Science ®Google Scholar
• Kivits, G. A. A., and Hora, J. (1975). A convenient preparation of 3-(1H-imidazol-4-yl)propanol. J. Heterocyc. Chem., 12, 577.
   Web of Science ®Google Scholar
• Rival, Y., Grassy, G., and Michel, G. (1992). Synthesis and antibacterial activity of some imidazo [1,2a]pyrimidin derivatives. Chem. Pharm. Bull., 40, 1170–1176.
   PubMed Web of Science ®Google Scholar
• Gabriel, S., and Pinkus, G. (1893). Zur kenntniss der amidoke-tone. Berichte, 26, 2197–2209.
   Google Scholar
• Grant, R. L., and Pyman, F. L. (1921). The nitro- and amino-derivatives of 4-phenylglyoxaline. J. Chem. Soc., 119, 1893- 1903.
   Google Scholar
• Sadao, M., Mamoru, S., Tameo, I., Kazuo, M., and Yoshio, I. (1984). Synthesis of 2-mercapto-4-substituted imidazole derivatives with antiinflammatory properties. Chem. Pharm. Bull., 32, 2536–2543.
   PubMed Web of Science ®Google Scholar
• Kjellin, G., and Sandström, J. (1969). Tautomeric cyclic thiones. Part III. Preparation of N - and S-methyl derivatives of some azoline-2-thiones. Acta Chem. Scand., 23, 2879–2887.
   Google Scholar
• Cramer, R. D., III, Patterson, D. E., and Bunce, J. D. (1988). Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc., 110, 5959–5967.
   PubMed Web of Science ®Google Scholar
• (a) Klebe, G., Abraham, U., and Mietzner, T. (1994). Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem., 37, 4130–4146. (b) Klebe, G., and Abraham, U. (1999). Comparative molecular similarity index analysis (CoMSIA) to study hydrogen-bonding properties and to score combinatorial libraries. J. Comput.-Aided Mol. Design, 13, 1- 10.
   PubMed Web of Science ®Google Scholar
• Mor, M., Plazzi, P. V., Bordi, F., Rivara, S., Crivori, P., Gaillard, P., Carrupt, P.-A., and Testa, B. (1996). Structure-affinity relationships of H3 receptor ligands. Presented at the 11th European Symposium on QSAR, Lausanne, Switzerland, Abstract P-1.D.
   Google Scholar
• Cheng, Y. C., and Prussoff, W. H. (1973). Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% of inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol., 22, 3099–3108.
   PubMed Web of Science ®Google Scholar
• Sybyl v. 6.6, October 1999. Tripos Inc., 1699 South Hanley Rd., St. Louis, Missouri, 63144, USA.
   Google Scholar
• Clark, M., Cramer, R. D., III, and Van Opdenbosch, N. (1989). Validation of the general purpose Tripos 5.2 force field. J. Comput. Chem., 10, 982–1012.
   Web of Science ®Google Scholar
• Powell, M. J. D. (1977). Restart procedures for the conjugate gradient method. Math. Program., 12, 241–254.
   Web of Science ®Google Scholar
• Plazzi, P. V., Bordi, F., Mor, M., Cozzini, P., and Domiano, P. (1997). H3-receptor antagonists: Conformational analysis of thioperamide and X-ray crystal 3D-QSAR ANALYSIS OF H3 RECEPTOR ANTAGONISTS 79
   Google Scholar
• Cramer, R. D., III, Bunce, J. D., and Patterson, D. E. (1988). Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quantum Struct.-Act. Relat., 7, 18- 25.
   Web of Science ®Google Scholar
• Cruciani, G., Clementi, S., and Baroni, M. (1993). Variable selection in PLS analysis. In 3D QSAR in Drug Design. Theory Methods and Applications, edited by H. Kubinyi, Leiden: ESCOM, p. 552. structure of the analog N-cyclohexyl-4-methylpiperidine-1-carbothioamide. Farmaco, 6-7, 399–404.
   Google Scholar
• Sybyl 6.6 Ligand-Based Manual, pp. 133–146.
   Google Scholar
• Sybyl 6.6 Ligand-Based Manual, pp. 147–150.
   Google Scholar
• Sybyl 6.6 Force Field Manual, p. 164.
   Google Scholar
• Wold, S., Ruhe, A., Wold, H., and Dunn, W. J. (1984). The covariance problem in linear regression. The partial least squares (PLS) approach to generalized inverses. SIAM J. Sci. Stat. Comput., 5, 735–743.
   Web of Science ®Google Scholar